SEMGLEE- insulin glargine-yfgn injection, solution
Mylan Specialty L.P.
----------
HIGHLIGHTS OF PRESCRIBING INFORMATIONThese highlights do not include all the information needed to use SEMGLEE safely and effectively. See full prescribing information for SEMGLEE.
SEMGLEE® (insulin glargine-yfgn) injection, for subcutaneous use Initial U.S. Approval: 2021 SEMGLEE® (insulin glargine-yfgn) is interchangeable* with LANTUS (insulin glargine). INDICATIONS AND USAGEDOSAGE AND ADMINISTRATION
DOSAGE FORMS AND STRENGTHSCONTRAINDICATIONSWARNINGS AND PRECAUTIONS
ADVERSE REACTIONSAdverse reactions commonly associated with insulin glargine products include hypoglycemia, allergic reactions, injection site reactions, lipodystrophy, pruritus, rash, edema and weight gain. (6.1)
To report SUSPECTED ADVERSE REACTIONS, contact Mylan at 1-877-446-3679 (1-877-4-INFO-RX) or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. DRUG INTERACTIONS
* An interchangeable product (IP) is a biological product that is approved based on data demonstrating that it is highly similar to an FDA-approved reference product (RP) and that there are no clinically meaningful differences between the products; it can be expected to produce the same clinical result as the RP in any given patient; and if administered more than once to a patient, the risk in terms of safety or diminished efficacy from alternating or switching between use of the RP and IP is not greater than that from the RP without such alternation or switch. Interchangeability of SEMGLEE has been demonstrated for the condition(s) of use, strength(s), dosage form(s), and route(s) of administration described in its Full Prescribing Information.
See 17 for PATIENT COUNSELING INFORMATION and FDA-approved patient labeling. Revised: 7/2021 |
FULL PRESCRIBING INFORMATION
1 INDICATIONS AND USAGE
SEMGLEE is indicated to improve glycemic control in adults and pediatric patients with type 1 diabetes mellitus and in adults with type 2 diabetes mellitus.
Limitations of Use
SEMGLEE is not recommended for the treatment of diabetic ketoacidosis.
2 DOSAGE AND ADMINISTRATION
2.1 Important Administration Instructions
- •
- Administer SEMGLEE subcutaneously once daily at any time of day but at the same time every day.
- •
- Prior to initiation of SEMGLEE, train patients on proper use and injection technique.
- •
- Patient should follow the Instructions for Use to correctly administer SEMGLEE.
- •
- Administer SEMGLEE subcutaneously into the abdominal area, thigh, or deltoid, and rotate injection sites within the same region from one injection to the next to reduce the risk of lipodystrophy and localized cutaneous amyloidosis. Do not inject into areas of lipodystrophy or localized cutaneous amyloidosis [see Warnings and Precautions (5.2), Adverse Reactions (6)].
- •
- During changes to a patient’s insulin regimen, increase the frequency of blood glucose monitoring [see Warnings and Precautions (5.2)].
- •
- Visually inspect SEMGLEE vials and prefilled pens for particulate matter and discoloration prior to administration. Only use if the solution is clear and colorless with no visible particles.
- •
- The SEMGLEE prefilled pen dials in 1-unit increments.
- •
- Use SEMGLEE prefilled pen with caution in patients with visual impairment who may rely on audible clicks to dial their dose.
- •
- Refrigerate unused (unopened) SEMGLEE vials and prefilled pens.
- •
- Do not administer intravenously or via an insulin pump.
- •
- Do not dilute or mix SEMGLEE with any other insulin or solution.
- •
- The SEMGLEE prefilled pen is for single patient use only [see Warnings and Precautions (5.1)].
2.2 General Dosing Instructions
- •
- Individualize and adjust the dosage of SEMGLEE based on the individual’s metabolic needs, blood glucose monitoring results and glycemic control goal.
- •
- Dosage adjustments may be needed with changes in physical activity, changes in meal patterns (i.e., macronutrient content or timing of food intake), during acute illness, or changes in renal or hepatic function. Dosage adjustments should only be made under medical supervision with appropriate glucose monitoring [see Warnings and Precautions (5.2)].
2.3 Initiation of SEMGLEE Therapy
Type 1 Diabetes
- •
- In patients with type 1 diabetes, SEMGLEE must be used concomitantly with short-acting insulin. The recommended starting dose of SEMGLEE in patients with type 1 diabetes should be approximately one-third of the total daily insulin requirements. Short-acting, premeal insulin should be used to satisfy the remainder of the daily insulin requirements.
Type 2 Diabetes
- •
- The recommended starting dose of SEMGLEE in patients with type 2 diabetes who are not currently treated with insulin is 0.2 units/kg or up to 10 units once daily. One may need to adjust the amount and timing of short- or rapid-acting insulins and dosages of any oral antidiabetic drugs.
2.4 Changing to SEMGLEE from Other Insulin Therapies
- •
- If changing patients from once-daily insulin glargine, 300 units/mL, to once-daily SEMGLEE, the recommended initial SEMGLEE dose is 80% of the insulin glargine, 300 units/mL dose that is being discontinued. This dose reduction will lower the likelihood of hypoglycemia [see Warnings and Precautions (5.3)].
- •
- If changing from a treatment regimen with an intermediate or long-acting insulin to a regimen with SEMGLEE, a change in the dose of the basal insulin may be required and the amount and timing of the shorter-acting insulins and doses of any oral antidiabetic drugs may need to be adjusted.
- •
- If changing patients from once-daily NPH insulin to once-daily SEMGLEE, the recommended initial SEMGLEE dose is the same as the dose of NPH that is being discontinued.
- •
- If changing patients from twice-daily NPH insulin to once-daily SEMGLEE, the recommended initial SEMGLEE dosage is 80% of the total NPH dose that is being discontinued. This dosage reduction will lower the likelihood of hypoglycemia [see Warnings and Precautions (5.3)].
3 DOSAGE FORMS AND STRENGTHS
Injection: 100 units per mL (U-100) clear and colorless solution available as:
- •
- 10 mL multiple-dose vial
- •
- 3 mL single-patient-use prefilled pen
4 CONTRAINDICATIONS
SEMGLEE is contraindicated:
- •
- during episodes of hypoglycemia [see Warnings and Precautions (5.3)].
- •
- in patients with hypersensitivity to insulin glargine products or any of the excipients in SEMGLEE [see Warnings and Precautions (5.5)].
5 WARNINGS AND PRECAUTIONS
5.1 Never Share a SEMGLEE Prefilled Pen, Syringe, or Needle Between Patients
SEMGLEE prefilled pens must never be shared between patients, even if the needle is changed. Patients using SEMGLEE vials must never re-use or share needles or syringes with another person. Sharing poses a risk for transmission of blood-borne pathogens.
5.2 Hyperglycemia or Hypoglycemia with Changes in Insulin Regimen
Changes in an insulin regimen (e.g., insulin strength, manufacturer, type, injection site or method of administration) may affect glycemic control and predispose to hypoglycemia [see Warnings and Precautions (5.3)] or hyperglycemia. Repeated insulin injections into areas of lipodystrophy or localized cutaneous amyloidosis have been reported to result in hyperglycemia; and a sudden change in the injection site (to unaffected area) has been reported to result in hypoglycemia [see Adverse Reactions (6)].
Make any changes to a patient’s insulin regimen under close medical supervision with increased frequency of blood glucose monitoring. Advise patients who have repeatedly injected into areas of lipodystrophy or localized cutaneous amyloidosis to change the injection site to unaffected areas and closely monitor for hypoglycemia. For patients with type 2 diabetes, dosage adjustments of concomitant oral and antidiabetic products may be needed.
5.3 Hypoglycemia
Hypoglycemia is the most common adverse reaction associated with insulins, including insulin glargine products. Severe hypoglycemia can cause seizures, may be life-threatening or cause death. Hypoglycemia can impair concentration ability and reaction time; this may place an individual and others at risk in situations where these abilities are important (e.g., driving or operating other machinery).
Hypoglycemia can happen suddenly, and symptoms may differ in each individual and change over time in the same individual. Symptomatic awareness of hypoglycemia may be less pronounced in patients with longstanding diabetes, in patients with diabetic nerve disease, in patients using medications that block the sympathetic nervous system (e.g., beta-blockers) [see Drug Interactions (7)], or in patients who experience recurrent hypoglycemia.
Risk Factors for Hypoglycemia
The risk of hypoglycemia after an injection is related to the duration of action of the insulin and, in general, is highest when the glucose lowering effect of the insulin is maximal. As with all insulin preparations, the glucose lowering effect time course of insulin glargine products may vary in different individuals or at different times in the same individual and depends on many conditions, including the area of injection as well as the injection site blood supply and temperature [see Clinical Pharmacology (12.2)].
Other factors which may increase the risk of hypoglycemia include changes in meal pattern (e.g., macronutrient content or timing of meals), changes in level of physical activity, or changes to coadministered medication [see Drug Interactions (7)]. Patients with renal or hepatic impairment may be at higher risk of hypoglycemia [see Use in Specific Populations (8.6, 8.7)].
Risk Mitigation Strategies for Hypoglycemia
Patients and caregivers must be educated to recognize and manage hypoglycemia. Self-monitoring of blood glucose plays an essential role in the prevention and management of hypoglycemia. In patients at higher risk for hypoglycemia and patients who have reduced symptomatic awareness of hypoglycemia, increased frequency of blood glucose monitoring is recommended.
The long-acting effect of insulin glargine products may delay recovery from hypoglycemia.
5.4 Medication Errors
Accidental mix-ups among insulin products, particularly between long-acting insulins and rapid-acting insulins, have been reported. To avoid medication errors between SEMGLEE and other insulins, instruct patients to always check the insulin label before each injection [see Adverse Reactions (6.3)].
5.5 Hypersensitivity and Allergic Reactions
Severe, life-threatening, generalized allergy, including anaphylaxis, can occur with insulins, including insulin glargine products. If hypersensitivity reactions occur, discontinue SEMGLEE; treat per standard of care and monitor until symptoms and signs resolve [see Adverse Reactions (6.1)]. SEMGLEE is contraindicated in patients who have had hypersensitivity reactions to insulin glargine products or one of the excipients in SEMGLEE [see Contraindications (4)].
5.6 Hypokalemia
All insulins, including insulin glargine products, cause a shift in potassium from the extracellular to intracellular space, possibly leading to hypokalemia. Untreated hypokalemia may cause respiratory paralysis, ventricular arrhythmia, and death. Monitor potassium levels in patients at risk for hypokalemia, if indicated (e.g., patients using potassium-lowering medications, patients taking medications sensitive to serum potassium concentrations).
5.7 Fluid Retention and Heart Failure with Concomitant Use of PPAR-gamma Agonists
Thiazolidinediones (TZDs), which are peroxisome proliferator-activated receptor (PPAR)-gamma agonists, can cause dose-related fluid retention, particularly when used in combination with insulin. Fluid retention may lead to or exacerbate heart failure. Patients treated with insulin including SEMGLEE, and a PPAR-gamma agonist should be observed for signs and symptoms of heart failure. If heart failure develops, it should be managed according to current standards of care, and discontinuation or dose reduction of the PPAR-gamma agonist must be considered.
6 ADVERSE REACTIONS
The following adverse reactions are discussed elsewhere:
- •
- Hypoglycemia [see Warnings and Precautions (5.3)]
- •
- Hypersensitivity and allergic reactions [see Warnings and Precautions (5.5)]
- •
- Hypokalemia [see Warnings and Precautions (5.6)]
6.1 Clinical Trials Experience
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in clinical trials of a drug cannot be directly compared to rates in the clinical trial of another drug and may not reflect the rates observed in practice.
The data in Table 1 reflect the exposure of 2327 patients with type 1 diabetes to insulin glargine or NPH. The type 1 diabetes population had the following characteristics: Mean age was 38.5 years. Fifty four percent were male, 96.9% were Caucasian, 1.8% were Black or African American and 2.7% were Hispanic. The mean BMI was 25.1 kg/m2.
The data in Table 2 reflect the exposure of 1563 patients with type 2 diabetes to insulin glargine or NPH. The type 2 diabetes population had the following characteristics: Mean age was 59.3 years. Fifty eight percent were male, 86.7% were Caucasian, 7.8% were Black or African American and 9% were Hispanic. The mean BMI was 29.2 kg/m2.
The frequencies of adverse events during insulin glargine clinical trials in patients with type 1 diabetes mellitus and type 2 diabetes mellitus are listed in the tables below.
|
||
|
Insulin Glargine, (n = 1257) |
NPH,% (n = 1070) |
|
|
Upper respiratory tract infection |
22.4 |
23.1 |
|
Infection* |
9.4 |
10.3 |
|
Accidental injury |
5.7 |
6.4 |
|
Headache |
5.5 |
4.7 |
|
||
|
Insulin Glargine, (n = 849) |
NPH,% (n = 714) |
|
|
Upper respiratory tract infection |
11.4 |
13.3 |
|
Infection* |
10.4 |
11.6 |
|
Retinal vascular disorder |
5.8 |
7.4 |
|
Insulin Glargine, (n = 514) |
NPH,% (n = 503) |
|
|
Upper respiratory tract infection |
29.0 |
33.6 |
|
Edema peripheral |
20.0 |
22.7 |
|
Hypertension |
19.6 |
18.9 |
|
Influenza |
18.7 |
19.5 |
|
Sinusitis |
18.5 |
17.9 |
|
Cataract |
18.1 |
15.9 |
|
Bronchitis |
15.2 |
14.1 |
|
Arthralgia |
14.2 |
16.1 |
|
Pain in extremity |
13.0 |
13.1 |
|
Back pain |
12.8 |
12.3 |
|
Cough |
12.1 |
7.4 |
|
Urinary tract infection |
10.7 |
10.1 |
|
Diarrhea |
10.7 |
10.3 |
|
Depression |
10.5 |
9.7 |
|
Headache |
10.3 |
9.3 |
|
||
|
Insulin Glargine, (n = 174) |
NPH,% (n = 175) |
|
|
Infection* |
13.8 |
17.7 |
|
Upper respiratory tract infection |
13.8 |
16.0 |
|
Pharyngitis |
7.5 |
8.6 |
|
Rhinitis |
5.2 |
5.1 |
Severe Hypoglycemia
Hypoglycemia is the most commonly observed adverse reaction in patients using insulins, including insulin glargine products [see Warnings and Precautions (5.3)]. Tables 5, and 6, and 7 summarize the incidence of severe hypoglycemia in the insulin glargine individual clinical trials. Severe symptomatic hypoglycemia was defined as an event with symptoms consistent with hypoglycemia requiring the assistance of another person and associated with either a blood glucose below 50 mg/dL (≤ 56 mg/dL in the 5-year trial and ≤ 36 mg/dL in the ORIGIN trial) or prompt recovery after oral carbohydrate, intravenous glucose or glucagon administration.
Percentages of insulin glargine-treated adult patients experiencing severe symptomatic hypoglycemia in the insulin glargine clinical trials [see Clinical Studies (14)] were comparable to percentages of NPH-treated patients for all treatment regimens (see Tables 5 and 6). In the pediatric phase 3 clinical trial, children and adolescents with type 1 diabetes had a higher incidence of severe symptomatic hypoglycemia in the two treatment groups compared to the adult trials with type 1 diabetes.
|
Study A Type 1 Diabetes Adults 28 weeks In combination with regular insulin |
Study B Type 1 Diabetes Adults 28 weeks In combination with regular insulin |
Study C Type 1 Diabetes Adults 16 weeks In combination with insulin lispro |
Study D Type 1 Diabetes Pediatrics 26 weeks In combination with regular insulin |
|||||
|
Insulin Glargine N = 292 |
NPH N = 293 |
Insulin Glargine N = 264 |
NPH N = 270 |
Insulin Glargine N = 310 |
NPH N = 309 |
Insulin Glargine N = 174 |
NPH N = 175 |
|
|
Percent of |
10.6 |
15.0 |
8.7 |
10.4 |
6.5 |
5.2 |
23.0 |
28.6 |
|
Study E Type 2 Diabetes Adults 52 weeks In combination with oral agents |
Study F Type 2 Diabetes Adults 28 weeks
In combination with |
Study G Type 2 Diabetes Adults 5 years
In combination with |
||||
|
Insulin Glargine N = 289 |
NPH N = 281 |
Insulin Glargine N = 259 |
NPH N = 259 |
Insulin Glargine N = 513 |
NPH N = 504 |
|
|
Percent of |
1.7 |
1.1 |
0.4 |
2.3 |
7.8 |
11.9 |
Table 7 displays the proportion of patients experiencing severe symptomatic hypoglycemia in the insulin glargine and Standard Care groups in the ORIGIN Trial [see Clinical Studies (14)].
|
ORIGIN Trial Medium duration of follow-up: 6.2 years |
||
|
Insulin Glargine N = 6231 |
Standard Care N = 6273 |
|
|
Percent of patients |
5.6 |
1.8 |
Peripheral Edema
Some patients taking insulin glargine products have experienced sodium retention and edema, particularly if previously poor metabolic control is improved by intensified insulin therapy.
Lipodystrophy
Administration of insulin subcutaneously, including insulin glargine products, has resulted in lipoatrophy (depression in the skin) or lipohypertrophy (enlargement or thickening of tissue) in some patients [see Dosage and Administration (2.2)].
Insulin Initiation and Intensification of Glucose Control
Intensification or rapid improvement in glucose control has been associated with a transitory, reversible ophthalmologic refraction disorder, worsening of diabetic retinopathy, and acute painful peripheral neuropathy. However, long-term glycemic control decreases the risk of diabetic retinopathy and neuropathy.
Weight Gain
Weight gain has occurred with some insulin therapies including insulin glargine products and has been attributed to the anabolic effects of insulin and the decrease in glucosuria.
Allergic Reactions
Local Allergy
As with any insulin therapy, patients taking insulin glargine products may experience injection site reactions, including redness, pain, itching, urticaria, edema, and inflammation. In clinical studies in adult patients, there was a higher incidence of treatment-emergent injection site pain in insulin glargine-treated patients (2.7%) compared to NPH insulin-treated patients (0.7%). The reports of pain at the injection site did not result in discontinuation of therapy.
6.2 Immunogenicity
As with all therapeutic proteins, there is potential for immunogenicity. The detection of antibody formation is highly dependent on the sensitivity and specificity of the assay. Additionally, the observed incidence of antibody (including neutralizing antibody) positivity in an assay may be influenced by several factors, including assay methodology, sample handling, timing of sample collection, concomitant medications, and underlying disease. For these reasons, comparison of the incidence of antibodies in the studies described below with the incidence of antibodies in other studies or to other insulin glargine products may be misleading.
All insulin products can elicit the formation of insulin antibodies. The presence of such insulin antibodies may increase or decrease the efficacy of insulin and may require adjustment of the insulin dose. In phase 3 clinical trials of insulin glargine, increases in titers of antibodies to insulin were observed in NPH insulin and insulin glargine treatment groups with similar incidences.
6.3 Postmarketing Experience
The following adverse reactions have been identified during postapproval use of insulin glargine products. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.
Medication errors have been reported in which other insulins, particularly rapid-acting insulins, have been accidentally administered instead of insulin glargine products [see Patient Counseling Information (17)]. To avoid medication errors between SEMGLEE and other insulins, patients should be instructed to always verify the insulin label before each injection.
Localized cutaneous amyloidosis at the injection site has occurred. Hyperglycemia has been reported with repeated insulin injections into areas of localized cutaneous amyloidosis; hypoglycemia has been reported with a sudden change to an unaffected injection site.
7 DRUG INTERACTIONS
Table 8 includes clinically significant drug interactions with SEMGLEE.
|
Drugs that May Increase the Risk of Hypoglycemia |
|
|
Drugs: |
Antidiabetic agents, ACE inhibitors, angiotensin II receptor blocking agents, disopyramide, fibrates, fluoxetine, monoamine oxidase inhibitors, pentoxifylline, pramlintide, salicylates, somatostatin analogs (e.g., octreotide), and sulfonamide antibiotics. |
|
Intervention: |
Dose reductions and increased frequency of glucose monitoring may be required when SEMGLEE is coadministered with these drugs. |
|
Drugs that May Decrease the Blood Glucose Lowering Effect of SEMGLEE |
|
|
Drugs: |
Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones. |
|
Intervention: |
Dose increases and increased frequency of glucose monitoring may be required when SEMGLEE is coadministered with these drugs. |
|
Drugs that May Increase or Decrease the Blood Glucose Lowering Effect of SEMGLEE |
|
|
Drugs: |
Alcohol, beta-blockers, clonidine, and lithium salts. Pentamidine may cause hypoglycemia, which may sometimes be followed by hyperglycemia. |
|
Intervention: |
Dose adjustment and increased frequency of glucose monitoring may be required when SEMGLEE is coadministered with these drugs. |
|
Drugs that May Blunt Signs and Symptoms of Hypoglycemia |
|
|
Drugs: |
beta-blockers, clonidine, guanethidine, and reserpine |
|
Intervention: |
Increased frequency of glucose monitoring may be required when SEMGLEE is coadministered with these drugs. |
8 USE IN SPECIFIC POPULATIONS
8.1 Pregnancy
Risk Summary
Published studies with use of insulin glargine products during pregnancy have not reported a clear association with insulin glargine products and adverse developmental outcomes (see Data). There are risks to the mother and fetus associated with poorly controlled diabetes in pregnancy (see Clinical Considerations).
Rats and rabbits were exposed to insulin glargine in animal reproduction studies during organogenesis, respectively 50 times and 10 times the human subcutaneous dose of 0.2 units/kg/day. Overall, the effects of insulin glargine did not generally differ from those observed with regular human insulin (see Data).
The estimated background risk of major birth defects is 6% to 10% in women with pregestational diabetes with an HbA1c >7 and has been reported to be as high as 20% to 25% in women with a HbA1c >10. The estimated background risk of miscarriage for the indicated population is unknown. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively.
Clinical Considerations
Disease-associated maternal and/or embryo-fetal risk
Poorly controlled diabetes in pregnancy increases the maternal risk for diabetic ketoacidosis, preeclampsia, spontaneous abortions, preterm delivery, and delivery complications. Poorly controlled diabetes increases the fetal risk for major birth defects, stillbirth, and macrosomia-related morbidity.
Data
Human Data
Published data do not report a clear association with insulin glargine products and major birth defects, miscarriage, or adverse maternal or fetal outcomes when insulin glargine is used during pregnancy. However, these studies cannot definitely establish the absence of any risk because of methodological limitations including small sample size and some lacking comparator groups.
Animal Data
Subcutaneous reproduction and teratology studies have been performed with insulin glargine and regular human insulin in rats and Himalayan rabbits. Insulin glargine was given to female rats before mating, during mating, and throughout pregnancy at doses up to 0.36 mg/kg/day, which is approximately 50 times the recommended human subcutaneous starting dose of 0.2 units/kg/day (0.007 mg/kg/day), on a mg/kg basis. In rabbits, doses of 0.072 mg/kg/day, which is approximately 10 times the recommended human subcutaneous starting dose of 0.2 units/kg/day on a mg/kg basis, were administered during organogenesis. The effects of insulin glargine did not generally differ from those observed with regular human insulin in rats or rabbits. However, in rabbits, five fetuses from two litters of the high-dose group exhibited dilation of the cerebral ventricles. Fertility and early embryonic development appeared normal.
8.2 Lactation
Risk Summary
There are either no or only limited data on the presence of insulin glargine products in human milk, the effects on breastfed infant, or the effects on milk production. Endogenous insulin is present in human milk. The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for SEMGLEE, and any potential adverse effects on the breastfed child from SEMGLEE or from the underlying maternal condition.
8.4 Pediatric Use
The safety and effectiveness of insulin glargine products have been established in pediatric patients (age 6 to 15 years) with type 1 diabetes [see Clinical Studies (14.2)]. The safety and effectiveness of insulin glargine products in pediatric patients younger than 6 years of age with type 1 diabetes and pediatric patients with type 2 diabetes have not been established.
The dosage recommendation when changing to SEMGLEE in pediatric patients (age 6 to 15 years) with type 1 diabetes is the same as that described for adults [see Dosage and Administration (2.2, 2.4), Clinical Studies (14)]. As in adults, the dosage of SEMGLEE must be individualized in pediatric patients (age 6 to 15 years) with type 1 diabetes based on metabolic needs and frequent monitoring of blood glucose.
In the pediatric clinical trial, pediatric patients (age 6 to 15 years) with type 1 diabetes had a higher incidence of severe symptomatic hypoglycemia compared to the adults in trials with type 1 diabetes [see Adverse Reactions (6.1)].
8.5 Geriatric Use
Of the total number of subjects in controlled clinical studies of patients with type 1 and type 2 diabetes who were treated with insulin glargine, 15% were ≥ 65 years of age and 2% were ≥ 75 years of age. The only difference in safety or effectiveness in the subpopulation of patients ≥ 65 years of age compared to the entire study population was a higher incidence of cardiovascular events typically seen in an older population in the insulin glargine and NPH treatment groups.
Nevertheless, caution should be exercised when SEMGLEE is administered to geriatric patients. In elderly patients with diabetes, the initial dosing, dose increments, and maintenance dosage should be conservative to avoid hypoglycemic reactions. Hypoglycemia may be difficult to recognize in the elderly.
8.6 Hepatic Impairment
The effect of hepatic impairment on the pharmacokinetics of insulin glargine products has not been studied. Frequent glucose monitoring and dose adjustment may be necessary for SEMGLEE in patients with hepatic impairment [see Warnings and Precautions (5.3)].
8.7 Renal Impairment
The effect of renal impairment on the pharmacokinetics of insulin glargine products has not been studied. Some studies with human insulin have shown increased circulating levels of insulin in patients with renal failure. Frequent glucose monitoring and dose adjustment may be necessary for SEMGLEE in patients with renal impairment [see Warnings and Precautions (5.3)].
10 OVERDOSAGE
Excess insulin administration may cause hypoglycemia and hypokalemia [see Warnings and Precautions (5.3, 5.6)]. Mild episodes of hypoglycemia can usually be treated with oral carbohydrates. Adjustments in drug dosage, meal patterns, or exercise may be needed.
More severe episodes of hypoglycemia with coma, seizure, or neurologic impairment may be treated with intramuscular/subcutaneous glucagon or concentrated intravenous glucose. After apparent clinical recovery from hypoglycemia, continued observation and additional carbohydrate intake may be necessary to avoid recurrence of hypoglycemia. Hypokalemia must be corrected appropriately.
11 DESCRIPTION
Insulin glargine-yfgn is a long-acting human insulin analog produced by recombinant DNA technology utilizing a recombinant yeast strain, Pichia pastoris. Insulin glargine-yfgn is a parenteral blood-glucose-lowering agent [see Clinical Pharmacology (12)]. Insulin glargine-yfgn has low aqueous solubility at neutral pH. At pH 4 insulin glargine-yfgn is completely soluble. After injection into the subcutaneous tissue, the acidic solution is neutralized, leading to formation of microprecipitates from which small amounts of insulin glargine-yfgn are slowly released, resulting in a relatively constant concentration/time profile over 24 hours with no pronounced peak. This profile allows once-daily dosing as a basal insulin. Insulin glargine-yfgn differs from human insulin in that the amino acid asparagine at position A21 is replaced by glycine and two arginines are added to the C-terminus of the B-chain. Chemically, insulin glargine-yfgn is 21A-Gly-30Ba-L-Arg-30Bb-L-Arg-human insulin and has the empirical formula C267H404N72O78S6 and a molecular weight of 6063 Da. In vivo assay confirms the minimum potency of insulin glargine-yfgn is NLT 15 units/mg.
Insulin glargine-yfgn has the following structural formula:
SEMGLEE (insulin glargine-yfgn) injection is a sterile, clear and colorless solution for subcutaneous use in a 10 mL multiple-dose vial and a 3 mL single-patient-use prefilled pen.
Vial
Each mL contains 100 units of insulin glargine-yfgn and the inactive ingredients: glycerol (20 mg), metacresol (2.7 mg), polysorbate-20 (20 mcg), zinc chloride (content adjusted to provide 30 mcg zinc ion), and Water for Injection, USP.
Prefilled pen
Each mL contains 100 units of insulin glargine-yfgn and the inactive ingredients: glycerol (20 mg), metacresol (2.7 mg), zinc chloride (content adjusted to provide 30 mcg zinc ion), and Water for Injection, USP.
The pH is adjusted by addition of aqueous solutions of hydrochloric acid and/or sodium hydroxide. SEMGLEE has a pH of approximately 4.
12 CLINICAL PHARMACOLOGY
12.1 Mechanism of Action
The primary activity of insulin, including insulin glargine products, is regulation of glucose metabolism. Insulin and its analogs lower blood glucose by stimulating peripheral glucose uptake, especially by skeletal muscle and fat, and by inhibiting hepatic glucose production. Insulin inhibits lipolysis and proteolysis and enhances protein synthesis.
12.2 Pharmacodynamics
In clinical studies, the glucose-lowering effect on a molar basis (i.e., when given at the same doses) of intravenous insulin glargine is approximately the same as that for human insulin. Figure 1 shows results from a study in patients with type 1 diabetes conducted for a maximum of 24 hours after the injection. The median time between injection and the end of pharmacological effect was 14.5 hours (range: 9.5 to 19.3 hours) for NPH insulin, and 24 hours (range: 10.8 to > 24.0 hours) (24 hours was the end of the observation period) for insulin glargine.
* Determined as amount of glucose infused to maintain constant plasma glucose levels
The duration of action after abdominal, deltoid, or thigh subcutaneous administration was similar. The time course of action of insulins, including insulin glargine products, may vary between individuals and within the same individual.
12.3 Pharmacokinetics
Absorption and Bioavailability
After subcutaneous injection of insulin glargine in healthy subjects and in patients with diabetes, the insulin serum concentrations indicated a slower, more prolonged absorption and a relatively constant concentration/time profile over 24 hours with no pronounced peak in comparison to NPH insulin.
Metabolism and Elimination
A metabolism study in humans indicates that insulin glargine is partly metabolized at the carboxyl terminus of the B chain in the subcutaneous depot to form two active metabolites with in vitro activity similar to that of human insulin, M1 (21A-Gly-insulin) and M2 (21A-Gly-des- 30B-Thr-insulin). Unchanged drug and these degradation products are also present in the circulation.
Special Populations
Age, Race, and Gender
Effect of age, race, and gender on the pharmacokinetics of insulin glargine products has not been evaluated. However, in controlled clinical trials in adults (n = 3890) and a controlled clinical trial in pediatric patients (n = 349), subgroup analyses based on age, race, and gender did not show differences in safety and efficacy between insulin glargine and NPH insulin [see Clinical Studies (14)].
Obesity
Effect of Body Mass Index (BMI) on the pharmacokinetics of insulin glargine products has not been evaluated.
13 NONCLINICAL TOXICOLOGY
13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility
In mice and rats, standard two-year carcinogenicity studies with insulin glargine were performed at doses up to 0.455 mg/kg, which was for the rat approximately 65 times the recommended human subcutaneous starting dose of 0.2 units/kg/day (0.007 mg/kg/day) on a mg/kg basis. Histiocytomas were found at injection sites in male rats and mice in acid vehicle containing groups and are considered a response to chronic tissue irritation and inflammation in rodents. These tumors were not found in female animals, in saline control, or insulin comparator groups using a different vehicle.
Insulin glargine was not mutagenic in tests for detection of gene mutations in bacteria and mammalian cells (Ames and HGPRT-test) and in tests for detection of chromosomal aberrations (cytogenetics in vitro in V79 cells and in vivo in Chinese hamsters).
In a combined fertility and prenatal and postnatal study of insulin glargine in male and female rats at subcutaneous doses up to 0.36 mg/kg/day, which was approximately 50 times the recommended human subcutaneous starting dose of 0.2 units/kg/day (0.007 mg/kg/day) maternal toxicity due to dose-dependent hypoglycemia, including some deaths, was observed. Consequently, a reduction of the rearing rate occurred in the high-dose group only. Similar effects were observed with NPH insulin.
14 CLINICAL STUDIES
14.1 Overview of Clinical Studies
The safety and effectiveness of insulin glargine given once-daily at bedtime was compared to that of once-daily and twice-daily NPH insulin in open-label, randomized, active-controlled, parallel studies of 2,327 adult patients and 349 pediatric patients with type 1 diabetes mellitus and 1,563 adult patients with type 2 diabetes mellitus (see Tables 9-11). In general, the reduction in glycated hemoglobin (HbA1c) with insulin glargine was similar to that with NPH insulin.
14.2 Clinical Studies in Adult and Pediatric Patients with Type 1 Diabetes
In two clinical studies (Studies A and B), patients with type 1 diabetes (Study A; n = 585, Study B n = 534) were randomized to 28 weeks of basal-bolus treatment with insulin glargine or NPH insulin. Regular human insulin was administered before each meal. Insulin glargine was administered at bedtime. NPH insulin was administered either as once daily at bedtime or in the morning and at bedtime when used twice daily.
In Study A, the average age was 39.2 years. The majority of patients were White (99%) and 55.7% were male. The mean BMI was approximately 24.9 kg/m2. The mean duration of diabetes was 15.5 years.
In Study B, the average age was 38.5 years. The majority of patients were White (95.3%) and 50.6% were male. The mean BMI was approximately 25.8 kg/m2. The mean duration of diabetes was 17.4 years.
In another clinical study (Study C), patients with type 1 diabetes (n = 619) were randomized to 16 weeks of basal-bolus treatment with insulin glargine or NPH insulin. Insulin lispro was used before each meal. Insulin glargine was administered once daily at bedtime and NPH insulin was administered once or twice daily. The average age was 39.2 years. The majority of patients were White (96.9%) and 50.6% were male. The mean BMI was approximately 25.6 kg/m2. The mean duration of diabetes was 18.5 years.
In these 3 studies, insulin glargine and NPH insulin had similar effects on HbA1c (Table 9) with a similar overall rate of severe symptomatic hypoglycemia [see Adverse Reactions (6.1)].
|
Treatment duration Treatment in combination with |
Study A 28 weeks Regular insulin |
Study B 28 weeks Regular insulin |
Study C 16 weeks Insulin lispro |
|||
|
Insulin Glargine |
NPH |
Insulin Glargine |
NPH |
Insulin Glargine |
NPH |
|
|
Number of subjects treated |
292 |
293 |
264 |
270 |
310 |
309 |
|
HbA1c |
||||||
|
Baseline HbA1c |
8.0 |
8.0 |
7.7 |
7.7 |
7.6 |
7.7 |
|
Adjusted mean change at trial end |
+0.2 |
+0.1 |
-0.2 |
-0.2 |
-0.1 |
-0.1 |
|
Treatment Difference (95% CI) |
+0.1 (0.0; +0.2) |
+0.1 (-0.1; +0.2) |
0.0 (-0.1; +0.1) |
|||
|
Basal insulin dose |
||||||
|
Baseline mean |
21 |
23 |
29 |
29 |
28 |
28 |
|
Mean change from baseline |
-2 |
0 |
-4 |
+2 |
-5 |
+1 |
|
Total insulin dose |
||||||
|
Baseline mean |
48 |
52 |
50 |
51 |
50 |
50 |
|
Mean change from baseline |
-1 |
0 |
0 |
+4 |
-3 |
0 |
|
Fasting blood glucose (mg/dL) |
||||||
|
Baseline mean |
167 |
166 |
166 |
175 |
175 |
173 |
|
Adj. mean change from baseline |
-21 |
-16 |
-20 |
-17 |
-29 |
-12 |
|
Body weight (kg) |
||||||
|
Baseline mean |
73.2 |
74.8 |
75.5 |
75.0 |
74.8 |
75.6 |
|
Mean change from baseline |
0.1 |
-0.0 |
0.7 |
1.0 |
0.1 |
0.5 |
Type 1 Diabetes – Pediatric (see Table 10)
In a randomized, controlled clinical study (Study D), pediatric patients (age range 6 to 15 years) with type 1 diabetes (n = 349) were treated for 28 weeks with a basal-bolus insulin regimen where regular human insulin was used before each meal. Insulin glargine was administered once daily at bedtime and NPH insulin was administered once or twice daily. The average age was 11.7 years. The majority of patients were White (96.8%) and 51.9% were male. The mean BMI was approximately 18.9 kg/m2. The mean duration of diabetes was 4.8 years. Similar effects on HbA1c (Table 10) were observed in both treatment groups [see Adverse Reactions (6.1)].
|
Treatment duration Treatment in combination with |
Study D 28 weeks Regular insulin |
|
|
Insulin Glargine |
NPH+ Regular Insulin |
|
|
Number of subjects treated |
174 |
175 |
|
HbA1c |
||
|
Baseline mean |
8.5 |
8.8 |
|
Change from baseline (adjusted mean) |
+0.3 |
+0.3 |
|
Difference from NPH (adjusted mean) |
0.0 |
|
|
(95% CI) |
(-0.2; +0.3) |
|
|
Basal insulin dose |
||
|
Baseline mean |
19 |
19 |
|
Mean change from baseline |
-1 |
+2 |
|
Total insulin dose |
||
|
Baseline mean |
43 |
43 |
|
Mean change from baseline |
+2 |
+3 |
|
Fasting blood glucose (mg/dL) |
||
|
Baseline mean |
194 |
191 |
|
Mean change from baseline |
-23 |
-12 |
|
Body weight (kg) |
||
|
Baseline mean |
45.5 |
44.6 |
|
Mean change from baseline |
2.2 |
2.5 |
14.3 Clinical Studies in Adults with Type 2 Diabetes
In a randomized, controlled clinical study (Study E) (n = 570), insulin glargine was evaluated for 52 weeks in combination with oral anti-diabetic medications (a sulfonylurea, metformin, acarbose, or combinations of these drugs). The average age was 59.5 years. The majority of patients were White (92.8%) and 53.7% were male. The mean BMI was approximately 29.1 kg/m2. The mean duration of diabetes was 10.3 years. Insulin glargine administered once daily at bedtime was as effective as NPH insulin administered once daily at bedtime in reducing HbA1c and fasting glucose (Table 11). The rate of severe symptomatic hypoglycemia was similar in insulin glargine and NPH insulin treated patients [see Adverse Reactions (6.1)].
In a randomized, controlled clinical study (Study F), in patients with type 2 diabetes not using oral antidiabetic medications (n = 518), a basal-bolus regimen of insulin glargine once daily at bedtime or NPH insulin administered once or twice daily was evaluated for 28 weeks. Regular human insulin was used before meals, as needed. The average age was 59.3 years. The majority of patients were White (80.7%) and 60% were male. The mean BMI was approximately 30.5 kg/m2. The mean duration of diabetes was 13.7 years. Insulin glargine had similar effectiveness as either once- or twice-daily NPH insulin in reducing HbA1c and fasting glucose (Table 11) with a similar incidence of hypoglycemia [see Adverse Reactions (6.1)].
In a randomized, controlled clinical study (Study G), patients with type 2 diabetes were randomized to 5 years of treatment with once-daily insulin glargine or twice-daily NPH insulin. For patients not previously treated with insulin, the starting dose of insulin glargine or NPH insulin was 10 units daily. Patients who were already treated with NPH insulin either continued on the same total daily NPH insulin dose or started insulin glargine at a dose that was 80% of the total previous NPH insulin dose. The primary endpoint for this study was a comparison of the progression of diabetic retinopathy by 3 or more steps on the Early Treatment Diabetic Retinopathy Study (ETDRS) scale. HbA1c change from baseline was a secondary endpoint. Similar glycemic control in the 2 treatment groups was desired in order to not confound the interpretation of the retinal data. Patients or study personnel used an algorithm to adjust the insulin glargine and NPH insulin doses to a target fasting plasma glucose ≤ 100 mg/dL. After the insulin glargine or NPH insulin dose was adjusted, other anti-diabetic agents, including premeal insulin were to be adjusted or added. The average age was 55.1 years. The majority of patients were White (85.3%) and 53.9% were male. The mean BMI was approximately 34.3 kg/m2. The mean duration of diabetes was 10.8 years. The insulin glargine group had a smaller mean reduction from baseline in HbA1c compared to the NPH insulin group, which may be explained by the lower daily basal insulin doses in the insulin glargine group (Table 11). The incidences of severe symptomatic hypoglycemia were similar between groups [see Adverse Reactions (6.1)].
|
||||||
|
Treatment duration Treatment in combination with |
Study E 52 weeks Oral agents |
Study F 28 weeks Regular insulin |
Study G 5 years Regular insulin |
|||
|
Insulin Glargine |
NPH |
Insulin Glargine |
NPH |
Insulin Glargine |
NPH |
|
|
Number of subjects treated |
289 |
281 |
259 |
259 |
513 |
504 |
|
HbA1c |
||||||
|
Baseline mean |
9.0 |
8.9 |
8.6 |
8.5 |
8.4 |
8.3 |
|
Adjusted mean change from |
-0.5 |
-0.4 |
-0.4 |
-0.6 |
-0.6 |
-0.8 |
|
Insulin Glargine ‒ NPH |
-0.1 |
+0.2 |
+0.2 |
|||
|
95% CI for Treatment difference |
(-0.3; +0.1) |
(0.0; +0.4) |
(+0.1; +0.4) |
|||
|
Basal insulin dose* |
||||||
|
Baseline mean |
14 |
15 |
44.1 |
45.5 |
39 |
44 |
|
Mean change from baseline |
+12 |
+9 |
-1 |
+7 |
+23 |
+30 |
|
Total insulin dose* |
||||||
|
Baseline mean |
14 |
15 |
64 |
67 |
48 |
53 |
|
Mean change from baseline |
+12 |
+9 |
+10 |
+13 |
+41 |
+40 |
|
Fasting blood glucose (mg/dL) |
||||||
|
Baseline mean |
179 |
180 |
164 |
166 |
190 |
180 |
|
Adj. mean change from baseline |
-49 |
-46 |
-24 |
-22 |
-45 |
-44 |
|
Body weight (kg) |
||||||
|
Baseline mean |
83.5 |
82.1 |
89.6 |
90.7 |
100 |
99 |
|
Adj. mean change from baseline |
2.0 |
1.9 |
0.4 |
1.4 |
3.7 |
4.8 |
Insulin Glargine Timing of Daily Dosing (see Table 12)
The safety and efficacy of insulin glargine administered pre-breakfast, pre-dinner, or at bedtime were evaluated in a randomized, controlled clinical study in patients with type 1 diabetes (study H, n = 378). Patients were also treated with insulin lispro at mealtime. The average age was 40.9 years. All patients were White (100%) and 53.7% were male. The mean BMI was approximately 25.3 kg/m2. The mean duration of diabetes was 17.3 years. Insulin glargine administered at different times of the day resulted in similar reductions in HbA1c compared to that with bedtime administration (see Table 12). In these patients, data are available from 8-point home glucose monitoring. The maximum mean blood glucose was observed just prior to injection of insulin glargine regardless of time of administration.
In this study, 5% of patients in the insulin glargine-breakfast arm discontinued treatment because of lack of efficacy. No patients in the other two arms discontinued for this reason. The safety and efficacy of insulin glargine administered pre-breakfast or at bedtime were also evaluated in a randomized, active-controlled clinical study (Study I, n = 697) in patients with type 2 diabetes not adequately controlled on oral anti-diabetic therapy. All patients in this study also received glimepiride 3 mg daily. The average age was 60.8 years. The majority of patients were White (96.6%) and 53.7% were male. The mean BMI was approximately 28.7 kg/m2. The mean duration of diabetes was 10.1 years. Insulin glargine given before breakfast was at least as effective in lowering HbA1c as insulin glargine given at bedtime or NPH insulin given at bedtime (see Table 12).
|
Treatment duration Treatment in Combination with: |
Study H 24 weeks Insulin lispro |
Study I 24 weeks Glimepiride |
||||
|
Insulin Glargine Breakfast |
Insulin Glargine Dinner |
Insulin Glargine Bedtime |
Insulin Glargine Breakfast |
Insulin Glargine Bedtime |
NPH Bedtime |
|
|
Number of subjects treated* |
112 |
124 |
128 |
234 |
226 |
227 |
|
HbA1c |
||||||
|
Baseline mean |
7.6 |
7.5 |
7.6 |
9.1 |
9.1 |
9.1 |
|
Mean change from baseline |
-0.2 |
-0.1 |
0.0 |
-1.3 |
-1.0 |
-0.8 |
|
Basal insulin dose (U) |
||||||
|
Baseline mean |
22 |
23 |
21 |
19 |
20 |
19 |
|
Mean change from baseline |
5 |
2 |
2 |
11 |
18 |
18 |
|
Total insulin dose (U) |
||||||
|
Baseline mean |
52 |
52 |
49 |
NA† |
NA |
NA |
|
Mean change from baseline |
2 |
3 |
2 | |||
|
Body weight (kg) |
||||||
|
Baseline mean |
77.1 |
77.8 |
74.5 |
80.7 |
82 |
81 |
|
Mean change from baseline |
0.7 |
0.1 |
0.4 |
3.9 |
3.7 |
2.9 |
Five-Year Trial Evaluating the Progression of Retinopathy
Retinopathy was evaluated in the insulin glargine clinical studies by analysis of reported retinal adverse events and fundus photography. The numbers of retinal adverse events reported for insulin glargine and NPH insulin treatment groups were similar for patients with type 1 and type 2 diabetes.
Insulin glargine was compared to NPH insulin in a 5-year randomized clinical trial that evaluated the progression of retinopathy as assessed with fundus photography using a grading protocol derived from the Early Treatment Diabetic Retinopathy Scale (ETDRS). Patients had type 2 diabetes (mean age 55 years) with no (86%) or mild (14%) retinopathy at baseline. Mean baseline HbA1c was 8.4%. The primary outcome was progression by 3 or more steps on the ETDRS scale at study endpoint. Patients with pre-specified post-baseline eye procedures (pan-retinal photocoagulation for proliferative or severe nonproliferative diabetic retinopathy, local photocoagulation for new vessels, and vitrectomy for diabetic retinopathy) were also considered as 3-step progressors regardless of actual change in ETDRS score from baseline. Retinopathy graders were blinded to treatment group assignment. The results for the primary endpoint are shown in Table 13 for both the per-protocol and Intent-to-Treat populations and indicate similarity of insulin glargine to NPH in the progression of diabetic retinopathy as assessed by this outcome.
|
Insulin Glargine |
NPH (%) |
95% CI for difference |
||
|
Per-protocol |
53/374 (14.2%) |
57/363 (15.7%) |
-2.0% (2.6%) |
-7.0% to +3.1% |
|
Intent-to-Treat |
63/502 (12.5%) |
71/487 (14.6%) |
-2.1% (2.1%) |
-6.3% to +2.1% |
The Origin Study
The Outcome Reduction with Initial Glargine Intervention trial (i.e., ORIGIN) was an open-label, randomized, 2-by-2, factorial design study. One intervention in ORIGIN compared the effect of insulin glargine to standard care on major adverse cardiovascular outcomes in 12,537 participants ≥ 50 years of age with abnormal glucose levels (i.e., impaired fasting glucose [IFG] and/or impaired glucose tolerance [IGT]) or early type 2 diabetes mellitus and established cardiovascular (i.e., CV) disease or CV risk factors at baseline.
The objective of the trial was to demonstrate that use of insulin glargine could significantly lower the risk of major cardiovascular outcomes compared to standard care. Two coprimary composite cardiovascular endpoints were used in ORIGIN. The first coprimary endpoint was the time to first occurrence of a major adverse cardiovascular event defined as the composite of CV death, nonfatal myocardial infarction and nonfatal stroke. The second coprimary endpoint was the time to the first occurrence of CV death or nonfatal myocardial infarction or nonfatal stroke or revascularization procedure or hospitalization for heart failure.
Participants were randomized to either insulin glargine (N = 6264) titrated to a goal fasting plasma glucose of ≤ 95 mg/dL or to standard care (N = 6273). Anthropometric and disease characteristics were balanced at baseline. The mean age was 64 years and 8% of participants were 75 years of age or older. The majority of participants were male (65%). Fifty nine percent were Caucasian, 25% were Latin, 10% were Asian and 3% were Black. The median baseline BMI was 29 kg/m2. Approximately 12% of participants had abnormal glucose levels (IGT and/or IFG) at baseline and 88% had type 2 diabetes. For patients with type 2 diabetes, 59% were treated with a single oral antidiabetic drug, 23% had known diabetes but were on no antidiabetic drug and 6% were newly diagnosed during the screening procedure. The mean HbA1c (SD) at baseline was 6.5% (1.0). Fifty-nine percent of participants had had a prior cardiovascular event and 39% had documented coronary artery disease or other cardiovascular risk factors.
Vital status was available for 99.9% and 99.8% of participants randomized to insulin glargine and standard care respectively at end of trial. The median duration of follow-up was 6.2 years (range: 8 days to 7.9 years). The mean HbA1c (SD) at the end of the trial was 6.5% (1.1) and 6.8% (1.2) in the insulin glargine and standard care group respectively. The median dose of insulin glargine at end of trial was 0.45 U/kg. Eighty-one percent of patients randomized to insulin glargine were using insulin glargine at end of the study. The mean change in body weight from baseline to the last treatment visit was 2.2 kg greater in the insulin glargine group than in the standard care group.
Overall, the incidence of major adverse cardiovascular outcomes was similar between groups (see Table 14). All-cause mortality was also similar between groups.
|
Insulin Glargine |
Standard Care N = 6273 |
Insulin Glargine vs Standard Care |
|
|
n (Events per 100 PY) |
n (Events per 100 PY) |
Hazard Ratio (95% CI) |
|
|
Coprimary endpoints |
|||
|
CV death, nonfatal myocardial infarction, or nonfatal stroke |
1041 (2.9) |
1013 (2.9) |
1.02 (0.94, 1.11) |
|
CV death, nonfatal myocardial infarction, nonfatal stroke, hospitalization for heart failure or revascularization procedure |
1792 (5.5) |
1727 (5.3) |
1.04 (0.97, 1.11) |
|
Components of coprimary endpoints |
|||
|
CV death |
580 |
576 |
1.00 (0.89, 1.13) |
|
Myocardial Infarction (fatal or nonfatal) |
336 |
326 |
1.03 (0.88, 1.19) |
|
Stroke (fatal or nonfatal) |
331 |
319 |
1.03 (0.89, 1.21) |
|
Revascularizations |
908 |
860 |
1.06 (0.96, 1.16) |
|
Hospitalization for heart failure |
310 |
343 |
0.90 (0.77, 1.05) |
In the ORIGIN trial, the overall incidence of cancer (all types combined) or death from cancer (Table 15) was similar between treatment groups.
|
Insulin Glargine |
Standard Care N = 6273 |
Insulin Glargine vs Standard Care |
|
|
n (Events per 100 PY) |
n (Events per 100 PY) |
Hazard Ratio (95% CI) |
|
|
Cancer endpoints |
|||
|
Any cancer event (new or recurrent) |
559 (1.56) |
561 (1.56) |
0.99 (0.88, 1.11) |
|
New cancer events |
524 (1.46) |
535 (1.49) |
0.96 (0.85, 1.09) |
|
Death due to Cancer |
189 (0.51) |
201 (0.54) |
0.94 (0.77, 1.15) |
16 HOW SUPPLIED/STORAGE AND HANDLING
16.1 How Supplied
SEMGLEE (insulin glargine-yfgn) injection is supplied as a clear and colorless solution 100 units/mL (U-100) available as:
|
SEMGLEE |
Dose Increment |
NDC Number |
Package Size |
|
10 mL multiple-dose vial |
n/a |
49502-250-80 |
1 vial |
|
3 mL single-patient-use prefilled pen |
1 unit |
49502-251-71 |
1 pen |
|
49502-251-73 |
3 pens |
||
|
49502-251-75 |
5 pens |
The SEMGLEE prefilled pen dials in 1-unit increments.
Needles are not included in the packs.
BD® Ultra-Fine needles are compatible with this pen.
16.2 Storage
Dispense in the original sealed carton with the enclosed Instructions for Use.
SEMGLEE should not be stored in the freezer and should not be allowed to freeze. Discard SEMGLEE if it has been frozen. Protect SEMGLEE from direct heat and light.
Storage conditions are summarized in the following table:
|
Not in-use (unopened) Refrigerated (2° to 8°C [36° to 46°F]) |
Not in-use (unopened) Room Temperature (up to 30°C [86°F]) |
In-use (opened) (see temperature below) |
|
|
10 mL multiple-dose vial |
Until expiration date |
28 days |
28 days Refrigerated or room temperature |
|
3 mL single-patient-use prefilled pen |
Until expiration date |
28 days |
28 days Room temperature only (Do not refrigerate) |
17 PATIENT COUNSELING INFORMATION
Advise the patient to read the FDA-approved patient labeling (Patient Information and Instructions for Use).
Never Share a SEMGLEE Prefilled Pen or Syringe Between Patients
Advise patients that they must never share a SEMGLEE prefilled pen with another person, even if the needle is changed. Advise patients using SEMGLEE vials not to re-use or share needles or syringes with another person. Sharing carries a risk for transmission of blood-borne pathogens [see Warnings and Precautions (5.1)].
Hyperglycemia or Hypoglycemia
Inform patients that hypoglycemia is the most common adverse reaction with insulin. Inform patients of the symptoms of hypoglycemia. Inform patients that the ability to concentrate and react may be impaired as a result of hypoglycemia. This may present a risk in situations where these abilities are especially important, such as driving or operating other machinery. Advise patients who have frequent hypoglycemia or reduced or absent warning signs of hypoglycemia to use caution when driving or operating machinery [see Warnings and Precautions (5.3)].
Advise patients that changes in insulin regimen can predispose to hyperglycemia or hypoglycemia and that changes in insulin regimen should be made under close medical supervision [see Warnings and Precautions (5.2)].
Medications Errors
Instruct patients to always check the insulin label before each injection [see Warnings and Precautions (5.4)].
Administration
Advise patients that SEMGLEE must NOT be diluted or mixed with any other insulin or solution and that SEMGLEE must only be used if the solution is clear and colorless with no particles visible [see Dosage and Administration (2.1)].
BD is a registered trademark of Becton, Dickinson, and Company.
Manufactured by:
Mylan Pharmaceuticals Inc.
Morgantown, West Virginia 26505 U.S.A.
U.S. License No. 2210
INGLIJK:R1
Patient Information
|
SEMGLEE® (Sehm-GLEE)
|
|
Do not share your syringes with other people, even if the needle has been changed. You may give other people a serious infection, or get a serious infection from them. What is SEMGLEE? SEMGLEE is a long-acting man-made insulin used to control high blood sugar in adults with diabetes mellitus.
|
|
Who should not use SEMGLEE? Do not use SEMGLEE if you:
|
|
What should I tell my healthcare provider before using SEMLGEE? Before using SEMGLEE, tell your healthcare provider about all your medical conditions including if you:
Tell your healthcare provider about all the medicines you take including prescription and over-the-counter medicines, vitamins, and herbal supplements. Before you start using SEMGLEE, talk to your healthcare provider about low blood sugar and how to manage it. |
|
How should I use SEMGLEE?
|
|
Your dose of SEMGLEE may need to change because of:
|
|
What should I avoid while using SEMGLEE? While using SEMGLEE do not:
|
|
What are the possible side effects of SEMGLEE and other insulins? SEMGLEE may cause serious side effects that can lead to death, including:
Get emergency medical help if you have: trouble breathing, shortness of breath, fast heartbeat, swelling of your face, tongue, or throat, sweating, extreme drowsiness, dizziness, confusion. The most common side effects of SEMGLEE include:
These are not all the possible side effects of SEMGLEE. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088. |
|
General information about the safe and effective use of SEMGLEE. Medicines are sometimes prescribed for purposes other than those listed in a Patient Information leaflet. Do not use SEMGLEE for a condition for which it was not prescribed. Do not give SEMGLEE to other people, even if they have the same symptoms that you have. It may harm them. This Patient Information leaflet summarizes the most important information about SEMGLEE. If you would like more information, talk with your healthcare provider. You can ask your pharmacist or healthcare provider for information about SEMGLEE that is written for healthcare professionals. |
|
What are the ingredients in SEMGLEE?
For more information, call Mylan at 1-877-446-3679 (1-877-4-INFO-RX). Manufactured for: Mylan Specialty L.P., Morgantown, WV 26505 U.S.A. Manufactured by: Mylan Pharmaceuticals Inc., Morgantown, WV 26505 U.S.A., U.S. License No. 2210, Product of Malaysia |
This Patient Information has been approved by the U.S. Food and Drug Administration
Approved: 7/2021
MA:B:PIV:INGLIJK:R1
Instructions for Use
SEMGLEE® (Sehm-GLEE)
(insulin glargine-yfgn) injection for subcutaneous use
10 mL Vial (100 Units/mL, U-100)
Read the Instructions for Use before you start taking SEMGLEE and each time you get a new SEMGLEE vial. There may be new information. This information does not take the place of talking to your healthcare provider about your medical condition or your treatment.
Do not share your SEMGLEE syringes with other people even if the needle has been changed. You may give other people a serious infection, or get a serious infection from them.
Supplies needed to give your injection:
- •
- a SEMGLEE 10 mL vial
- •
- a U-100 insulin syringe and needle
- •
- 2 alcohol swabs
- •
- 1 sharps container for throwing away used needles and syringes. See “Disposing of used needles and syringes” at the end of these instructions.
Preparing your SEMGLEE dose:
- •
- Wash your hands with soap and water or with alcohol.
- •
- Check the SEMGLEE label to make sure you are taking the right type of insulin. This is especially important if you use more than 1 type of insulin.
- •
- Check the insulin to make sure it is clear and colorless. Do not use SEMGLEE if it is colored or cloudy, or if you see particles in the solution.
- •
- Do not use SEMGLEE after the expiration date stamped on the label or 28 days after you first use it.
- •
- Always use a syringe that is marked for U-100 insulin. If you use a syringe other than a U-100 insulin syringe, you may get the wrong dose of insulin.
- •
- Always use a new syringe or needle for each injection. Do not reuse or share your syringes or needles with other people. You may give other people a serious infection or get a serious infection from them.
Step 1:
If you are using a new vial, remove the protective cap. Do not remove the rubber stopper.
Step 2:
Wipe the top of the vial with an alcohol swab. You do not have to shake the vial of SEMGLEE before use.
Step 3:
Draw air into the syringe equal to your insulin dose. Put the needle through the rubber top of the vial and push the plunger to inject the air into the vial.
Step 4:
Leave the syringe in the vial and turn both upside down. Hold the syringe and vial firmly in one hand. Make sure the tip of the needle is in the insulin. With your free hand, pull the plunger to withdraw the correct dose into the syringe.
Step 5:
Before you take the needle out of the vial, check the syringe for air bubbles. If bubbles are in the syringe, hold the syringe straight up and tap the side of the syringe until the bubbles float to the top. Push the bubbles out with the plunger and draw insulin back in until you have the correct dose.
Step 6:
Remove the needle from the vial. Do not let the needle touch anything. You are now ready to inject.
Giving your SEMGLEE injection:
- •
- Inject your insulin exactly as your healthcare provider has shown you.
- •
- Inject your insulin under the skin (subcutaneously) of your upper legs (thighs), upper arms, or stomach area (abdomen).
- •
- Change (rotate) your injection sites within the area you choose for each dose to reduce your risk of getting lipodystrophy (pits in the skin or thickened skin) and localized cutaneous amyloidosis (skin with lumps) at the injection sites.
- •
- Do not inject where the skin has pits, is thickened, or has lumps.
- •
- Do not inject where the skin is tender, bruised, scaly or hard, or into scars or damaged skin.
Step 7:
Choose your injection site. SEMGLEE is injected under the skin (subcutaneously) of your upper arm, thigh, or stomach area (abdomen). Wipe the skin with an alcohol swab to clean the injection site. Let the injection site dry before you inject your dose.
Step 8:
- •
- Pinch the skin.
- •
- Insert the needle in the way your healthcare provider showed you.
- •
- Release the skin.
- •
- Slowly push in the plunger of the syringe all the way, making sure you have injected all the insulin.
- •
- Leave the needle in the skin for about 10 seconds.
Step 9:
- •
- Pull the needle straight out of your skin.
- •
- Gently press the injection site for several seconds. Do not rub the area.
- •
- Do not recap the used needle. Recapping the needle can lead to a needle stick injury.
Disposing of used needles and syringes:
- •
- Put your used needles and syringes in a FDA-cleared sharps disposal container right away after use. Do not throw away (dispose of) loose needles and syringes in your household trash.
- •
- If you do not have a FDA-cleared sharps container, you may use a household container that is:
- o
- made of a heavy-duty plastic,
- o
- can be closed with a tight-fitting, puncture-resistant lid, without sharps being able to come out,
- o
- upright and stable during use,
- o
- leak resistant, and
- o
- properly labeled to warn of hazardous waste inside the container.
- •
- When your sharps disposal container is almost full, you will need to follow your community guidelines for the right way to dispose of your sharps disposal container. There may be state or local laws about how you should throw away used needles and syringes. For more information about safe sharps disposal, and for specific information about sharps disposal in the state that you live in, go to the FDA’s website at: http://www.fda.gov/safesharpsdisposal.
- •
- Do not dispose of your used sharps disposal container in your household trash unless your community guidelines permit this. Do not recycle your used sharps disposal container.
How should I store SEMGLEE?
- •
- Store unused SEMGLEE vials in the refrigerator at 36° to 46°F (2° to 8°C).
- •
- Store in-use (opened) SEMGLEE vials in a refrigerator or at room temperature up to 86°F (30°C).
- •
- Do not freeze SEMGLEE.
- •
- Keep SEMGLEE out of direct heat and light.
- •
- If a vial has been frozen or overheated, throw it away.
- •
- The SEMGLEE vials you are using should be thrown away after 28 days, even if it still has insulin left in it.
This Instructions for Use has been approved by the U.S. Food and Drug Administration.
Approved: 7/2021
SEMGLEE is a registered trademark of Mylan Pharmaceuticals Inc., a Viatris Company.
© 2021 Viatris Inc.
Manufactured by:
Mylan Pharmaceuticals Inc.
Morgantown, WV 26505 U.S.A.
U.S. License No. 2210
Manufactured for:
Mylan Specialty L.P.
Morgantown, WV 26505 U.S.A.
Product of Malaysia
MA:B:IFUV:INGLIJK:R1
Patient Information
|
SEMGLEE® (Sehm-GLEE) (insulin glargine-yfgn) injection for subcutaneous use, 100 units/mL (U-100) |
|
Do not share your SEMGLEE pen with other people, even if the needle has been changed. You may give other people a serious infection, or get a serious infection from them. What is SEMGLEE? SEMGLEE is a long-acting man-made insulin used to control high blood sugar in adults with diabetes mellitus.
|
|
Who should not use SEMGLEE? Do not use SEMGLEE if you:
|
|
What should I tell my healthcare provider before using SEMLGEE? Before using SEMGLEE, tell your healthcare provider about all your medical conditions including if you:
Tell your healthcare provider about all the medicines you take including prescription and over-the-counter medicines, vitamins, and herbal supplements. Before you start using SEMGLEE, talk to your healthcare provider about low blood sugar and how to manage it. |
|
How should I use SEMGLEE?
Keep SEMGLEE and all medicines out of the reach of children. |
|
Your dose of SEMGLEE may need to change because of:
|
|
What should I avoid while using SEMGLEE? While using SEMGLEE do not:
|
|
What are the possible side effects of SEMGLEE and other insulins? SEMGLEE may cause serious side effects that can lead to death, including:
Get emergency medical help if you have: trouble breathing, shortness of breath, fast heartbeat, swelling of your face, tongue, or throat, sweating, extreme drowsiness, dizziness, confusion. The most common side effects of SEMGLEE include:
These are not all the possible side effects of SEMGLEE. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088. |
|
General information about the safe and effective use of SEMGLEE. Medicines are sometimes prescribed for purposes other than those listed in a Patient Information leaflet. Do not use SEMGLEE for a condition for which it was not prescribed. Do not give SEMGLEE to other people, even if they have the same symptoms that you have. It may harm them. This Patient Information leaflet summarizes the most important information about SEMGLEE. If you would like more information, talk with your healthcare provider. You can ask your healthcare provider or pharmacist for information about SEMGLEE that is written for healthcare professionals. |
|
What are the ingredients in SEMGLEE?
For more information, call Mylan at 1-877-446-3679 (1-877-4-INFO-RX). Manufactured for: Mylan Specialty L.P., Morgantown, WV 26505 U.S.A. Manufactured by: Mylan Pharmaceuticals Inc, Morgantown, WV 26505 U.S.A., U.S. License No. 2210, Product of Malaysia |
This Patient Information has been approved by the U.S. Food and Drug Administration
Approved: 7/2021
SEMGLEE is a registered trademark of Mylan Pharmaceuticals Inc., a Viatris Company.
© 2021 Viatris Inc.
Manufactured by:
Mylan Pharmaceuticals Inc.
Morgantown, WV 26505 U.S.A.
U.S. License No. 2210
Manufactured for:
Mylan Specialty L.P.
Morgantown, WV 26505 U.S.A.
Product of Malaysia
MA:B:PIP:INGLIJK:R1
INSTRUCTIONS FOR USE
SEMGLEE® Single-Patient-Use Prefilled Pen
(insulin glargine-yfgn) injection
Your healthcare professional has decided that SEMGLEE is right for you. Talk with your healthcare professional about proper injection technique before using SEMGLEE.
Read these instructions carefully before using your SEMGLEE. If you are not able to follow all the instructions completely on your own, use SEMGLEE only if you have help from a person who is able to follow the instructions.
Do not share your SEMGLEE pen with other people, even if the needle has been changed. You may give other people a serious infection, or get a serious infection from them.
People who are blind or have vision problems should not use SEMGLEE single-patient-use prefilled pen without help from a person trained to use SEMGLEE single-patient-use prefilled pen.
Follow these instructions completely each time you use SEMGLEE to ensure that you get an accurate dose. If you do not follow these instructions you may get too much or too little insulin, which may affect your blood glucose.
SEMGLEE is a disposable pen for the injection of insulin. Each SEMGLEE contains in total 300 units of insulin. You can set doses from 1 to 80 units in steps of 1 unit. The pen plunger moves with each dose. The plunger will only move to the end of the cartridge when 300 units of insulin have been given.
Keep this leaflet for future reference.
If you have any questions about SEMGLEE or about diabetes, ask your healthcare professional, or call Mylan at 1-877-446-3679 (1-877-4-INFO-RX).
Important information for use of SEMGLEE:
- •
- Do not share your SEMGLEE pen with other people, even if the needle has been changed. You may give other people a serious infection, or get a serious infection from them.
- •
- Do not re-use needles. Always attach a new needle before each use.
- •
- BD® Ultra-Fine needles are compatible with SEMGLEE. These are sold separately and are manufactured by BD. Contact your healthcare professional for further information.
- •
- Always perform the safety test before each injection.
- •
- Do not select a dose or press the injection button without a needle attached.
- •
- If your injection is given by another person, special caution must be taken by this person to avoid accidental needle injury and transmission of infection.
- •
- Never use SEMGLEE if it is damaged or if you are not sure that it is working properly.
- •
- Always have a spare SEMGLEE in case your SEMGLEE is lost or damaged.
- •
- Change (rotate) your injection sites within the area you choose for each dose (see “Places to inject”).
Places to inject
- •
- Inject your insulin exactly as your healthcare professional has shown you.
- •
- Inject your insulin under the skin (subcutaneously) of your upper legs (thighs), upper arms, or stomach area (abdomen).
- •
- Change (rotate) your injection sites within the area you choose for each dose to reduce your risk of getting lipodystrophy (pits in skin or thickened skin) and localized cutaneous amyloidosis (skin with lumps) at the injection sites.
- •
- Do not inject where the skin has pits, is thickened, or has lumps.
- •
- Do not inject where the skin is tender, bruised, scaly or hard, or into scars or damaged skin.
Step 1. Check the insulin
- A.
- Check the label on your SEMGLEE to make sure you have the correct insulin. SEMGLEE is blue with a purple injection button.
- B.
- Take off the pen cap.
- C.
- Check the appearance of your insulin. SEMGLEE is a clear insulin. Do not use this SEMGLEE if the insulin is cloudy, colored or has particles.
Step 2. Attach the needle
Do not re-use needles. Always use a new sterile needle for each injection. This helps prevent contamination and potential needle blocks.
- A.
- Wipe the rubber seal with alcohol.
- B.
- Remove the protective seal from a new needle.
- C.
- Line up the needle with the pen, and keep it straight as you screw it on (See Figure a).
- •
- If the needle is not kept straight while you attach it, it can damage the rubber seal and cause leakage, or break the needle (See Figure b).
Step 3. Perform a Safety test
Always perform the safety test before each injection.
Performing the safety test ensures that you get an accurate dose by:
- •
- ensuring that pen and needle work properly
- •
- removing air bubbles
- A.
- Select a dose of 2 units by turning the white dose knob (See Figure c).
- B.
- Take off the outer needle cap and keep it to remove the used needle after injection. Take off the inner needle cap and discard it (See Figure d).
- C.
- Hold the pen with the needle pointing upwards.
- D.
- Tap the cartridge so that any air bubbles rise up towards the needle.
- E.
- Press the purple injection button all the way in. Check if insulin comes out of the needle tip (See Figure e).
You may have to perform the safety test several times before insulin is seen.
- •
- If no insulin comes out, check for air bubbles and repeat the safety test two more times to remove them.
- •
- If still no insulin comes out, the needle may be blocked. Change the needle and try again.
- •
- If no insulin comes out after changing the needle, your SEMGLEE may be damaged. Do not use this SEMGLEE.
Step 4. Select the dose
You can set the dose in steps of 1 unit, from a minimum of 1 unit to a maximum of 80 units. If you need a dose greater than 80 units, you should give it as two or more injections.
- A.
- Check that the dose window shows “0” following the safety test.
- B.
- Select your required dose (in the example below, the selected dose is 30 units, see Figure f). If you turn past your dose, you can turn back down.
- •
- Do not push the purple injection button while turning, as insulin will come out.
- •
- You cannot turn the white dose knob past the number of units left in the pen. Do not force the dosage selector to turn. In this case, either you can inject what is remaining in the pen and complete your dose with a new SEMGLEE or use a new SEMGLEE for your full dose.
Step 5. Inject the dose
- A.
- Use the injection method as instructed by your healthcare professional.
- B.
- Insert the needle into the skin (See Figure g).
- C.
- Deliver the dose by pressing the purple injection button in all the way. The number in the dose window will return to “0” as you inject. The white dose knob will turn, and you will hear “clicks” as you press down (See Figure h).
- D.
- Keep the purple injection button pressed all the way in.
Slowly count to 10 before you withdraw the needle from the skin. This ensures that the full dose will be delivered.
Step 6. Remove and discard the needle
Always remove the needle after each injection and store SEMGLEE without a needle attached. This helps prevent:
- •
- Contamination and/or infection
- •
- Entry of air into the insulin cartridge and leakage of insulin, which can cause inaccurate dosing.
- A.
- Put the outer needle cap back on the needle, and use it to unscrew the needle from the pen. To reduce the risk of accidental needle injury, never replace the inner needle cap.
- •
- If your injection is given by another person, special caution must be taken by this person when removing and disposing the needle. Follow recommended safety measures for removal and disposal of needles (e.g., a one-handed capping technique) in order to reduce the risk of accidental needle injury and transmission of infectious diseases.
- B.
- Dispose of the needle safely. Used needles should be placed in sharps containers (such as red biohazard containers), hard plastic containers (such as detergent bottles), or metal containers (such as an empty coffee can). Such containers should be sealed and disposed of properly. If you are giving an injection to another person, you should remove the needle in an approved manner to avoid needle-stick injuries.
- C.
- Always put the pen cap back on the pen, then store the pen until your next injection.
Storage Instructions
Please check the leaflet for the insulin for complete instructions on how to store SEMGLEE.
If your SEMGLEE is in cool storage, take it out 1 to 2 hours before you inject to allow it to warm up. Cold insulin is more painful to inject.
Keep SEMGLEE out of the reach and sight of children.
Keep your SEMGLEE in cool storage at 36° to 46°F (2° to 8°C) until first use. Do not allow it to freeze. Do not put it next to the freezer compartment of your refrigerator or next to a freezer pack.
Once you take your SEMGLEE out of cool storage, for use or as a spare, you can use it for up to 28 days. During this time it can be safely kept at room temperature up to 86°F (30°C). Do not use it after this time. SEMGLEE in use must not be stored in a refrigerator.
Do not use SEMGLEE after the expiration date printed on the label of the pen or on the carton.
Protect SEMGLEE from light.
Discard your used SEMGLEE as required by your local authorities.
Maintenance
Protect your SEMGLEE from dust and dirt.
You can clean the outside of your SEMGLEE by wiping it with a damp cloth.
Do not soak, wash, or lubricate the pen as this may damage it.
Your SEMGLEE is designed to work accurately and safely. It should be handled with care. Avoid situations where SEMGLEE might be damaged. If you are concerned that your SEMGLEE may be damaged, use a new one.
This Instructions for Use has been approved by the U.S. Food and Drug Administration.
Approved: 7/2021
BD is a registered trademark of Becton, Dickinson, and Company.
SEMGLEE is a registered trademark of Mylan Pharmaceuticals Inc., a Viatris Company.
© 2021 Viatris Inc.
Manufactured by:
Mylan Pharmaceuticals Inc.
Morgantown, WV 26505 U.S.A.
U.S. License No. 2210
Manufactured for:
Mylan Specialty L.P.
Morgantown, WV 26505 U.S.A.
Product of Malaysia
MA:B:IFUP:INGLIJK:R1
PRINCIPAL DISPLAY PANEL – 100 units/mL Pen
NDC 49502-251-75
Rx only
Semglee®
(insulin glargine-yfgn) injection
For Single Patient Use Only
100 units/mL (U-100)
For subcutaneous use only
Dispense in this sealed carton
Do not mix with other insulins
Use only if solution is clear and colorless with no particles visible
*Needles not included (see top panel)
Five 3 mL Prefilled Pens
Each mL contains 100 units of insulin glargine-yfgn, and inactive ingredients: glycerol (20 mg), metacresol (2.7 mg), zinc chloride (content adjusted to provide 30 mcg zinc ion), and Water for Injection, USP. The pH is approximately 4. The pH is adjusted by addition of aqueous solutions of hydrochloric acid and/or sodium hydroxide.
Recommended dosage: see Prescribing Information. As with any drug, if you are pregnant or nursing a baby, seek professional advice when using this product.
Any change of insulin should be made cautiously and only under medical supervision.
Storage: Refrigerate at 2º to 8ºC (36º to 46ºF) until first use. Avoid freezing. Discard if frozen. After first use of a SEMGLEE pen, store the pen at room temperature (up to 30ºC [86ºF]) and discard after 28 days. Protect from direct heat and light.
WARNING: Keep this and all medication out of the reach of children.
Use within 28 days after initial use.
*BD® Ultra-Fine needles are compatible with Semglee®. These are sold separately and manufactured by BD.
BD is a registered trademark of Becton, Dickinson, and Company.
SEMGLEE is a registered trademark of Mylan Pharmaceuticals Inc., a Viatris Company.
© 2021 Viatris Inc.
Manufactured by: Mylan Pharmaceuticals Inc.
Morgantown, WV 26505 U.S.A.
U.S. License No. 2210
Manufactured for: Mylan Specialty L.P.
Morgantown, WV 26505 U.S.A.
Product of Malaysia
MA:B:251:5C:R1
Mylan.com
PRINCIPAL DISPLAY PANEL – 100 units/mL Vial
NDC 49502-250-80 Rx only
Semglee®
(insulin glargine-yfgn) injection
100 units/mL (U-100)
Do not mix with other insulins
Use only if solution is clear and colorless with no particles visible
For subcutaneous use only
Use with U-100 syringe only
One 10 mL
Multiple-Dose
Vial
Each mL contains 100 units of insulin glargine-yfgn, and inactive ingredients: glycerol (20 mg), metacresol (2.7 mg),
polysorbate-20 (20 mcg), zinc chloride (content adjusted to provide 30 mcg zinc ion), and Water for Injection, USP. The pH is approximately 4. The pH is adjusted by addition of aqueous solutions of hydrochloric acid and/or sodium hydroxide.
Recommended dosage: see Prescribing Information. As with any drug, if you are pregnant or nursing a baby, seek professional advice when using this product. Any change of insulin should be made cautiously and only under medical supervision.
WARNING: Keep this and all medication out of the reach of children.
Manufactured by: Mylan Pharmaceuticals Inc.
Morgantown, WV 26505 U.S.A.
U.S. License No. 2210
Manufactured for: Mylan Specialty L.P.
Morgantown, WV 26505 U.S.A.
Product of Malaysia
Mylan.com
Storage: Refrigerate at 2º to 8ºC (36º to 46ºF) until first use. Avoid freezing. Discard if frozen.
After first use, store at room temperature (up to 30ºC [86ºF]) and discard after 28 days. Protect from direct heat and light.
SEMGLEE is a registered trademark of Mylan Pharmaceuticals Inc., a Viatris Company.
© 2021 Viatris Inc.
MA:B:25010:1C:R1
| SEMGLEE
insulin glargine-yfgn injection, solution |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| SEMGLEE
insulin glargine-yfgn injection, solution |
||||||||||||||||||||
|
||||||||||||||||||||
|
||||||||||||||||||||
|
||||||||||||||||||||
|
||||||||||||||||||||
|
||||||||||||||||||||
| Labeler - Mylan Specialty L.P. (194775557) |